**Activity**: PULSE Series Presentation

**Title:** To Be or Not To Be: Oral Lead-in for the Transition from Oral PrEP to Extended-release Intramuscular Cabotegravir

**Speaker:**

Julena Maurer, PharmD

PGY-1 Pharmacy Resident

UPMC Shadyside Hospital

**Objectives:**

* Identify the approved pharmacologic options for pre-exposure prophylaxis (PrEP) of human immunodeficiency virus (HIV)
* Describe the place in therapy of intramuscular cabotegravir for PrEP
* Discuss the risks and benefits of oral lead-in during the transition from oral PrEP therapy to extended-release intramuscular cabotegravir

**Presentation Abstract:**

Since the beginning of the HIV epidemic, 84.1 million people have been diagnosed and 47% of those people have died because of the disease. At the end of 2021 there were 38.4 million people living with an HIV diagnosis. However, infection rates decreased by 25% from 2015 to 2020. It is important for pharmacists to be able to recognize the various pharmacologic options available for pre-exposure prophylaxis (PrEP). It is also important for pharmacists to be able to weigh the risks and benefits of the pharmacologic options to identify the most appropriate therapy for various individuals. Recently, cabotegravir an extended-release injectable suspension has become available. Since its release in March of 2022, many patients have been switched from oral therapy to cabotegravir. Some clinicians believe when transitioning patients from oral therapy to cabotegravir an overlap of the 2 therapies is needed, while others believe this is not necessary to maintain adequate protection. For the purposes of this presentation, literature surrounding the transition to cabotegravir will be explored, with an additional focus on the pharmacokinetics of intramuscular cabotegravir.

**Format:**

* Live
* Home study
* Live and Home study

X Webinar (Live)

**Date of Live Activity:** March 8, 2023

**Activity length (hr. or CEU):** 1 hour

Topic Designators – activities are related to:

If a CPE activity’s target audience is exclusively for pharmacists, the designation “P” will be used as follows:

X 01-P Disease State Management/Drug therapy

* 02-P AIDS therapy
* 03-P Law (related to pharmacy practice)
* 04-P General Pharmacy
* 05-P Patient Safety
* 06-P Immunizations
* 07-P Compounding
* 08-P Pain Management/Opioids

****References:****

1. **World Health Organization (WHO int.). HIV. Available at** <https://www.who.int/data/gho/data/themes/hiv-aids#:~:text=Since%20the%20beginning%20of%20the,at%20the%20end%20of%202021>**. Accessed 1.22.23.**
2. Centers for Disease Control and Prevention (CDC). US Public Health Service: Pre-exposure Prophylaxis for the Prevention of HIV Infetion in the United States -2021.
3. Cabotegravir (Cabenuva) Package insert. Available at <https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF>. Accessed 1.22.23.
4. American Academy of HIV Medicine. Switching oral PREP to CAB. Available at <https://community.aahivm.org/communities/community-home/digestviewer/viewthread?GroupId=127&MessageKey=ececbd4f-5d92-4be4-b1c1-3cfe119b8f38&CommunityKey=322c843d-28d6-49c6-a952-3455159ae5ba>. Accessed 1.22.23.
5. Jaimie P. Meyer, Carolina R. Price, Yiwen Ye, Yilu Qin, DeShana Tracey, A. C. Demidont, Kathleen Melbourne, Frederick L. Altice, A PrEP Demonstration Project Using eHealth and Community Outreach to Justice-Involved Cisgender Women and Their Risk Networks, AIDS and Behavior, 10.1007/s10461-022-03709-2, (2022).
6. Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015 Jul;10(4):239-45. doi: 10.1097/COH.0000000000000168. PMID: 26049948; PMCID: PMC5638427.
7. Trezza, Christinea; Ford, Susan L.a; Spreen, Williama; Pan, Rennanb; Piscitelli, Stephena. Formulation and pharmacology of long-acting cabotegravir. Current Opinion in HIV and AIDS 10(4):p 239-245, July 2015. | DOI: 10.1097/COH.0000000000000168